{"id":"W2553893461","doi":"10.1182/blood.v116.21.5031.5031","title":"A Multicenter Randomized Phase II Trial of Mapatumumab, a TRAIL-R1 Agonist Monoclonal Antibody, In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma (MM)","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Internal medicine; Adverse effect; Refractory (planetary science); Surgery; Gastroenterology; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003212975,0.002071427,0.002626601,0.0004548693,0.0006017542,0.001029058,0.0009737334,0.001641812,0.00579422],"category_scores_gemma":[0.001930737,0.001060618,0.001583184,0.0004419454,0.001434029,0.0009199156,0.0004939851,0.003113931,0.001138862],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008303042,"about_ca_system_score_gemma":0.001738714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009210795,"about_ca_topic_score_gemma":0.00238443,"domain_scores_codex":[0.9987339,0.0008831485,0.00005575887,0.0001520168,0.00005141717,0.0001237375],"domain_scores_gemma":[0.9986764,0.0003382487,0.0002767962,0.0001143864,0.00008077082,0.0005134304],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9792563,0.007940917,0.0006209166,0.0001720404,0.0004057907,0.00003658909,0.00003571217,0.0002311029,0.003502564,0.00007275507,0.0007451329,0.006980238],"study_design_scores_gemma":[0.9413903,0.0570153,0.0007155233,0.000007020161,0.0001400165,0.00001486406,0.000007259705,0.0001900601,0.0002025714,0.00004796636,0.000263646,0.000005545725],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841297,0.002608236,0.0007760107,0.001138617,0.0005748651,0.00734447,0.001254971,0.0001334833,0.002039732],"genre_scores_gemma":[0.9795869,0.001679241,0.002429881,0.001965031,0.0007000924,0.008254007,0.00194239,0.00004295403,0.003399415],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00579422,"threshold_uncertainty_score":0.01938361,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0109801517532308,"score_gpt":0.2828969533631146,"score_spread":0.2719168016098838,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}